1

Flagship event for Mass Life Science Innovation to address question of creativity, June 3, 2014, in Boston

Image  for Life Science Innovation Day 2014

Image for Life Science Innovation Day 2014

On Tuesday, June 3, the Massachusetts Life Science Center (MLSC) will host  its 7th Mass Life Sciences Innovation  Day at the Harvard Club on Commonwealth Avenue, in Boston. Billed on its Website as “the biggest day for life sciences startups and innovation in the Commonwealth of Massachusetts,” Mass Life Science Innovation Day is  “a high-energy, hands-on event” at which scientific leaders and business experts mingle with scientists, post-docs, professors, entrepreneurs, innovators, and venture capitalists.  

“This is one of the best opportunities to hear about trends affecting life sciences start-ups and to learn about new technologies that are ready for commercialization, ”  according to Abigail Barrow, Director of the Massachusetts Technology Transfer Center and the conference chair,  

A central question to be addressed at the event involves creativity, according to Barrow. That is, can researchers still be creative with the organizational and financial demands that are placed on research environments?  Do corporations and academics still have the courage to allow their teams to be really creative? If you want to do interesting and exciting science can you still get the funding? How does business and finance leadership view creativity?

“Our speakers and panelists will discuss the current battle to create innovation friendly environments and its impact on entrepreneurs and young researchers finding jobs.”

The morning session will feature a keynote address by Mark Levin, who will speak about how Third Rock, the  venture capital firm he founded,  invests in new companies.

 Brock Reeve, Director of the Harvard Stem Cell Institute, will be the luncheon speaker.
Morning and afternoon breakout sessions featuring more than 40 speakers will cover scientific topics such as indication selection, experiment design and managing research programs as well as entrepreneurial topics including  “how to join the venture capital club,”  how to pitch your new idea, and “where to find money to fund your start-up.”

Some 30 early-stage companies and major research institutions will present posters and compete for prizes to be awarded at the close of the day by State Senator Karen Spilka.  The award-winners will be chosen by 20 Life Science CEOS and biotech leaders who will also attend a closing reception. The reception will include an Innovators Marketplace offering resources needed to commercialize an invention.

 More information on the program and registration is available on  the MLSC website at  –http://www.mattcenter.org/malsi-day-2014/home.html .

Here’s a link to the agenda and a complete list of speakers.
Conference fees range from $60 for students  to $550 for two marketplace exhibitors.

Massachusetts Life Sciences Innovation Day was  developed by the Massachusetts Life Sciences Start-up Initiative (MALSI)–a platform organization that brings together all major public and private entities in the State that are committed to building the next generation of Massachusetts companies. MALSI’s mission is to ensure that Massachusetts maintains its lead as the #1 region in the world to start, nurture and grow life sciences companies.  MALSI partners include: Massachusetts Technology Transfer Center, MassBio, Mass Medical Angels, TiE Boston, and several major universities and research hospitals.

–Anita M. Harris
Anita Harris is an author, photographer  and communications consultant based ib Cambridge, MA. 

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning PR and marketing firm based in Cambridge, MA. 




International & MA Cancer R&D Clusters Showcased at Whitehead Institute

Four Boston-area startups were among those showcased  in an international program on collaborative cancer research & therapy clusters held today at the Whitehead Institute in Kendall Square, Cambridge.

All four of the Boston companies are developing methods and technologies that aim to better diagnose or cure cancer; all are hopeful; all are seeking funding, investors, or purchasers.

The program, called the International Cancer Cluster Showcase,  was sponsored by Sanofi, which recently purchased Cambridge-based Genzyme  Corporation, and by cancer  research and treatment clusters in the Norway, the UK, France and  in Massachusetts.

The program was held in conjunction with the International Biotechnology Industry Organization (BIO) Convention, to start tomorrow.

In introducing the Boston area companies, Abigail Barrow of the Massachusetts Technology Transfer Center,  who chaired  the Boston and the overall sessions,  pointed out that Cambridge is, perhaps, the paramount biotechnology and cancer research center in the US.

  • AcuityBio, Inc. a Boston University Spinoff,  is developing a  biodegradable polymer mesh  to be implanted during cancer surgery for later, sustained use in local administration of cancer drugs, according to John Schwartz, the AcuitBio CEO.  The goal is to  prevent cancer recurrences in specific soft tissues thus improving the quality of patients’ lives, recucing the cost of care, increasing the length of disease-free progression and sigificantly improving cure rates for early stage cancer patients,  Schwartz said.
  • Joel Beriac, PhD, the president & CEO of Akrivis Technologies said that his company is developing an ultrasensitive ” Z-Tect,” (TM) technology platform that promises to allow much earlier cancer detection and more effective personalized therapies than is currently possible. Z-tect will save numerous lives and reduce healthcare costs by lowering “several thousand fold” the current limit-of-detection of early cancer biomarkers, imaging much smaller cancer lesions. Akrivis plans to ultimately develop, beyond ultrasenstivie diagnostics, safer and more efficacious targeted therapies.
  • BIOARRAY Therapeutics  is developing molecular diagnostics to improve cancer treatment decisions that are currently made on a trial-and-error basis, according to  Marcia V. Fournier, PhD, the BIOARRAY founder and CEO.  BIOARRAY’s core technology identifies relevant cancer biomarkers based on the normal biology and micro-environment representing underlying biological processes involved in the progression of tumors– independent of any specific patient set, cancer subgroup or treatment, Fournier said. The company’s lead diagnostic is a response prediction test for breast cancer–targeting the growing molecular diagnostics and personalized medicine markets.
  • CanThera Therapeutics is a development stage oncology therapeutics company built on technology from the Mass General Hospital laboratories and the Broad Institute.  According consultant Peter Leone, the investigators have found that a natural substance, piperlongumine (PL) appears to kill cancer cells by jamming the machinery that dissipates high oxidative stress (ROS). Normal cells have low levels of ROS and don’t need high levels of the antioxidant enzymes that PL stymies. CanThera aims to advance a selected novel analog of PL into the clinic in 2012.

The showcase also featured:


QUEBEC PRESENTERS:

Q-CROC (Quebec – Clinical Research Organization in Cancer)    http://qcroc.ca      

 

OSLO PRESENTERS:

 

TOULOUSE/CANCER BIO SANTE CLUSTER PRESENTERS

 

UK PRESENTERS

  • Acublate  Limited

 


Poster Session Companies

Oncocat: www.oncocat.org/principal.php?idiom=eng

AB-therapeutics: www.ab-therapeutics.com

Oryzon: www.oryzon.com/es/inicio 

 

–Anita M. Harris

 

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning strategic public relations,  marketing communications and thought leadership firm in Cambridge, MA.